Skip to content

EV / sales at other companies

Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
10,042.9×+9,939×
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
14.1×+3.2×
Arcus Biosciences logo
Arcus BiosciencesRCUS
11.1×+6.1×
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
308×+215×
Tango Therapeutics logo
Tango TherapeuticsTNGX
50.1×+47.1×
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
-154.1×-156×

Other financials

Income statement

See full
Revenue$3.0M-60.9%
Operating income-$78.6M+7.4%
Net income-$73.3M+4.9%
EPS (diluted)-$0.41+10.9%

Balance sheet

See full
Cash & equivalents$204.6M+119%
Total debt$31.6M-33.1%
Total equity$642.2M-10.9%
Total assets$699.6M-12.5%

Cash flow

See full
Operating cash flow-$51.1M+30.2%
CapEx$1.0K
Free cash flow-$44.9M+22.5%

Valuation

See full
Market cap$3.8B+300%

Profitability

See full
Operating margin-2,776.6%-820pp
Net margin-2,554.1%-745pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-40%-4.3pp
Debt / equity0.0×
Current ratio22.1×+2.2×

Where this comes from

Calculated from Relay Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relay Therapeutics, Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relay Therapeutics, Inc.'s EV / sales?
Relay Therapeutics, Inc. (RLAY) reported EV / sales of 150.4× in Q1 2026.
How has Relay Therapeutics, Inc.'s EV / sales changed year-over-year?
Relay Therapeutics, Inc.'s EV / sales increased by 190.3% year-over-year, from 51.8× to 150.4×.
What is the long-term trend for Relay Therapeutics, Inc.'s EV / sales?
Over 5 years (2020 to 2025), Relay Therapeutics, Inc.'s EV / sales has grown at a 18.0% compound annual growth rate (CAGR), from 40.2× to 92.1×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.